A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Ovarian Cancer Clinical Trial

Official title:

A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid Tumor

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01482715
• Other study ID #: CO-338-010
• Secondary ID: 2011-004250-26
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 2011
• Est. completion date: May 2019

Study information

• Verified date: June 2023
• Source: zr Pharma & GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Part 1 (Completed Enrollment) - The purpose of the first part of the study was to evaluate the safety of different doses and dosing regimens of oral rucaparib administered daily to patients with solid tumors. Part 2A (Completed Enrollment) and Part 2B (Completed Enrollment) - The purpose of the second part of the study is to determine the safety and clinical activity of the RP2D of oral rucaparib administered daily to patients with a known deleterious BRCA mutation (germline or somatic). Part 3 (Completed Enrollment) - The purpose of the third part of the study is to further evaluate PK of higher dose strength tablets at the RP2D in patients with any advanced solid tumor, inclusive of lymphoma, with evidence of a BRCA mutation (germline or somatic).

Description:

Rucaparib (CO-338; formerly known as PF 01367338 and AG 14699) is an orally available, small molecule inhibitor of poly-adenosine diphosphate [ADP] ribose polymerase (PARP) being developed for treatment of ovarian cancer associated with homologous recombination [HR] DNA repair deficiency (HRD). The safety and efficacy of rucaparib has been evaluated in several Phase 1 and Phase 2 studies. An oral formulation is the focus of current development efforts. Rucaparib is currently being investigated as monotherapy in patients with cancer associated with BRCA1 or BRCA2 mutations. For this study, it is anticipated that rucaparib will promote cell death in the BRCA-deficient tumor cells of ovarian cancer patients with evidence of a germline mutation, thereby limiting tumor progression and providing therapeutic benefit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 136
• Est. completion date: May 2019
• Est. primary completion date: March 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

The following eligibility criteria below pertain to patients enrolling into Part 2B of the study.

Inclusion Criteria:

• Have a known deleterious BRCA mutation (gBRCA or sBRCA) (as determined by a local laboratory that has received an international or country-specific, quality standards certification)
• Have evidence of measurable disease as defined by RECIST Version 1.1
• Have sufficient archival FFPE tumor tissue available for planned analyses. Archival tissue from the most recently collected biopsy or debulking surgery should be provided, if available.
• Have a histologically confirmed diagnosis of high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer
• Have received at least three prior chemotherapy regimens and have relapsed disease confirmed by radiologic assessment

Exclusion Criteria:

• Active second malignancy, i.e., patient known to have potentially fatal cancer present for which she may be (but not necessarily) currently receiving treatment a. Patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy was completed >6 months prior and/or bone marrow transplant (BMT) >2 years prior to first dose of rucaparib
• Prior treatment with any PARP inhibitor.
• Untreated or symptomatic central nervous system (CNS) metastases. Patients with asymptomatic CNS metastases are eligible provided they have been clinically stable for at least 4 weeks.
• Received treatment with chemotherapy, radiation, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs 14 days prior to first dose of rucaparib and/or ongoing adverse effects from such treatment > NCI CTCAE Grade 1 (Grade 2 non-hematologic toxicity to most recent treatment may be permitted with prior advanced approval from Sponsor).
• Hospitalization for bowel obstruction within 3 months prior to enrollment.

Related Conditions & MeSH terms

• Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
• Carcinoma, Ovarian Epithelial
• Fallopian Tube Cancer
• Fallopian Tube Neoplasms
• Ovarian Cancer
• Ovarian Neoplasms
• Peritoneal Cancer

Intervention

Drug:
• Rucaparib
Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre	Toronto	Ontario
Israel	Sheba Medical Center	Ramat Gan
Israel	Tel Aviv Sourasky Medical Center	Tel Aviv
Spain	Hospital Vall d'Hebron	Barcelona
United Kingdom	Institution of Cancer Science, University of Glasgow Wolfson Wohl Cancer Research	Glasgow	Scotland
United Kingdom	Guy's and St Thomas NHS Foundation Trust	London	England
United Kingdom	Imperial College Healthcare	London	England
United Kingdom	Royal Marsden NHS Foundation Trust	London	England
United Kingdom	University College London Cancer Institute	London
United Kingdom	Newcastle University	Newcastle Upon Tyne	England
United States	Dana-Farber Cancer Institute (Part 3 only)	Boston	Massachusetts
United States	Karmanos Cancer Institute	Detroit	Michigan
United States	Sarah Cannon Research Institute	Nashville	Tennessee
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	UCSF	San Francisco	California
United States	Sarah Cannon Research Institute	Sarasota	Florida

Sponsors (2)

Lead Sponsor	Collaborator
zr Pharma & GmbH	Foundation Medicine

Countries where clinical trial is conducted

United States,  Canada,  Israel,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate Per RECIST Version 1.1 (Part 2)	The confirmed response rate by RECIST v1.1 is defined as the proportion of patients with a confirmed Complete Response (CR) or Partial Response (PR) on subsequent tumor assessment at least 28 days after first response documentation.	Time from first dose to date of progression, up to approximately 8 months
Primary	Number of Participants With a Dose Limiting Toxicity (DLT)	The number of Part 1 (Phase 1) patients who experienced dose limiting toxicities after one cycle (21 days) of study drug.	Cycle 1 Day 1 to Cycle 1 Day 21
Primary	PK Profile of Rucaparib - Cmax (Part 1)	Cmax = maximum concentration following administration of rucaparib	Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days
Primary	PK Profile of Rucaparib - Tmax (Part 1)	Tmax = time to maximum concentration following administration of rucaparib	Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days
Primary	PK Profile of Rucaparib - AUC Last (Part 1)	AUC last = Area under the plasma concentration-time curve from time 0 to the last recorded observation	Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days
Secondary	Progression-free Survival (PFS) According to RECIST v1.1, as Assessed by the Investigator (Part 2)	PFS is calculated as 1+ the number of days from the first dose of study drug to disease progression by RECIST, as determined by the investigator or death due to any cause, whichever occurs first.	Cycle 1 Day 1 to End of Treatment, up to approximately 51 months
Secondary	Duration of Response Per RECIST Version 1.1 (Part 2)	Duration of response (DOR) for any confirmed RECIST CR or PR measured from the date of the first occurrence of a response until the first occurrence of PD per RECIST. For patients who continued treatment post-progression, the first date of progression was used for the analysis. Any patients with an ongoing response were censored at the date of the last post-baseline scan.	Cycle 1 Day 1 to End of Treatment, up to approximately 48 months
Secondary	Overall Survival (Part 2B)	Overall survival (OS) is defined as the number of days from the date of first dose of study drug to the date of death, due to any cause. Patients without a documented event of death will be censored on the date of their last visit.	Cycle 1 Day 1 to date of death, assessed up to 38 months
Secondary	Food Effect on PK of Rucaparib - Cmax (Part 1 and Part 3)	Cmax = maximum concentration following administration of rucaparib. The effect of food on rucaparib PK parameters was assessed over a 24-hour period in blood samples from a subset of patients. Patients were given a single dose of 40 mg or 300 mg rucaparib (Part 1), or 600 mg rucaparib (Part 3) and were randomized to one of two sequences where they were either Fed (with a high-fat meal) or Fasted (without a high-fat meal) on Day -7 or Cycle 1 Day 1. On each day, patients underwent blood sampling for PK at the specified time points. The median Fed and Fasted Cmax values were calculated for each arm.	Day -7 to Cycle 1 Day 1, or approximately 7 days
Secondary	Food Effect on PK of Rucaparib - Tmax (Part 1 and Part 3)	Tmax = time to maximum concentration following administration of rucaparib. The effect of food on rucaparib PK parameters was assessed over a 24-hour period in blood samples from a subset of patients. Patients were given a single dose of 40 mg or 300 mg rucaparib (Part 1), or 600 mg rucaparib (Part 3) and were randomized to one of two sequences where they were either Fed (with a high-fat meal) or Fasted (without a high-fat meal) on Day -7 or Cycle 1 Day 1. On each day, patients underwent blood sampling for PK at the specified time points. The median Fed and Fasted Tmax values were calculated for each arm.	Day -7 to Cycle 1 Day 1, or approximately 7 days
Secondary	Food Effect on PK of Rucaparib - AUC Last (Part 1 and Part 3)	AUC last = Area under the plasma concentration-time curve from time 0 to the last recorded observation. The effect of food on rucaparib PK parameters was assessed over a 24-hour period in blood samples from a subset of patients. Patients were given a single dose of 40 mg or 300 mg rucaparib (Part 1), or 600 mg rucaparib (Part 3) and were randomized to one of two sequences where they were either Fed (with a high-fat meal) or Fasted (without a high-fat meal) on Day -7 or Cycle 1 Day 1. On each day, patients underwent blood sampling for PK at the specified time points. The median Fed and Fasted AUC last values were calculated for each arm.	Day -7 to Cycle 1 Day 1, or approximately 7 days
Secondary	QTcF Value Change From Baseline (Part 1)	QTcF value change from baseline by daily dose corrected using Fridericia's method (QTcF). To evaluate the effects of rucaparib on the QT (interval from Q wave to T wave)/QTc (interval corrected for heart rate) interval, all patients underwent serial ECG monitoring at Screening, on Cycle 1 Day -1, Cycle 1 Day 1, Cycle 1 Day 15, Cycle 1 Day 22, on Day 1 of all subsequent cycles, at the EOT Visit, and as clinically indicated. Worst post-baseline QTcF value was used to categorize each patient.	Screening to End of Treatment, up to approximately 15 months